BID

The Real Good Food Company Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Retrieved on: 
Martedì, Aprile 23, 2024
Annual, Share (finance), Health, Annual report, Security (finance), Lung compliance, BID, Good, Calendar, Cryptocurrency

Per Listing Rule 5450(a)(1), the Company is provided with a grace period of 180 days, or until October 16, 2024, to meet the minimum bid price requirement under the Nasdaq Listing Rules.

Key Points: 
  • Per Listing Rule 5450(a)(1), the Company is provided with a grace period of 180 days, or until October 16, 2024, to meet the minimum bid price requirement under the Nasdaq Listing Rules.
  • The Company intends to monitor the closing bid price of its Shares during the grace period and will consider its options in order to regain compliance with Nasdaq’s minimum bid price requirement.
  • Regarding the notice of non-compliance with Nasdaq Listing Rule 5250(c)(1), under Nasdaq rules, the Company now has 60 calendar days (until June 18, 2024) to submit a plan to regain compliance.
  • There can be no assurance, however, that the Company will be able to regain compliance with the listing standards discussed above.

Southeastern Grocers strengthens commitment to building a more sustainable future with annual progress report and Earth Month initiatives

Retrieved on: 
Giovedì, Aprile 18, 2024
Retail, Environmental, Social and Governance (ESG), Sustainability, Continuing, Education, Professional Services, Philanthropy, Online Retail, Environment, Wine & Spirits, Fund Raising, Supermarket, Foundation, DEI (Diversity, Equity and Inclusion), Food, Beverage, Social, Harveys Supermarkets, Spouse, Winn-Dixie, Certification, Health, Hunger, BID, Sustainable Development Goals, Transport, EV, American Red Cross, ESG, Workforce, Multimedia, Paper, CO2, Organization

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The annual sustainability report offers a comprehensive overview of SEG’s support of the environment and its neighbors through ongoing corporate social responsibility efforts across the Southeast.
  • The grocer aligns its sustainability report with six specific United Nations Sustainable Development Goals, which address hunger, health, education, inequalities, responsible consumption and production, and ocean conservation.
  • In 2023, SEG, together with its charitable arm, the SEG Gives Foundation, donated more than $3.7 million to local communities.
  • To learn more about the grocer’s commitments and to view its 2023 sustainability report, visit segrocers.com/sustainability .

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Retrieved on: 
Martedì, Aprile 9, 2024
BID, Patient, Fluorouracil, 3D, MIA, Cancer, AACR, TGI, Pancreatic cancer, Paclitaxel, TGA, Annual general meeting, Medical imaging

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

Key Points: 
  • “We are evaluating a broad range of combinations for a variety of cancer types in our humanized 3D tumor growth assays, together with animal models.
  • The data we are sharing today at AACR clearly demonstrates IMM-1-104’s potential in combination with chemotherapy for pancreatic cancer.
  • IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
  • IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Lunedì, Aprile 1, 2024
Diagnosis, Research, Week, CD135, Administration, FMS, Growth, Menin, CLL, NSCLC, C-peptide, AML, BID, Diabetes, Insulin, Patient, Hypoglycemia, FLT3, G&A, Acute myeloid leukemia, Food, PDAC, Health Canada, Trial of the century, IND, Cancer, CRC, Safety, Research and development, Investment, FDA, DLBCL, DSM-IV codes, Pharmaceutical industry

In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.

Key Points: 
  • In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.
  • Cash position of $177.2 million at the end of the fourth quarter of 2023.
  • REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.
  • “2023 was a pivotal year for Biomea as we reported first positive data in type 2 diabetes and initiated our first clinical study in type 1 diabetes.

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Martedì, Marzo 26, 2024
Indian stock exchange, Absorption, Plasma, Exercise, Hanmi Pharmaceutical, AML, BID, Patient, APS, SAN, Venetoclax, G1, VEN, FLT3, EHA, LUX, Acute myeloid leukemia, Trial of the century, TUS, TSX, Hanmi, Azacitidine, G3, Pharmaceutical industry

This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.

Key Points: 
  • This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.
  • Total gross proceeds from the public offering were approximately $9.7 million before deducting underwriting costs, placement agent commissions and other offering-related expenses.
  • Private Placement – On January 31, 2024, Aptose closed a US $4 million private placement of common shares with strategic partner Hanmi Pharmaceutical.
  • Luxeptinib G3 Evaluation Completed – During 2023 and early 2024, clinical evaluation of the new generation 3 (G3) formulation of luxeptinib (LUX) was completed.

Global Cosmetovigilance Market to Surpass $4.6 Billion by 2028, Driven by Regulatory Focus and Consumer Awareness - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Aprile 8, 2024
Cosmetics, Retail, Element, Mocra, Growth, BID, EQUITY, Social media, Sale, Acquisition, Central Statistics Office (India), Big data, Risk assessment, Government

The cosmetovigilance market has seen a robust expansion, growing from $3.22 billion in 2023 to an expected $3.49 billion in 2024, with a compound annual growth rate (CAGR) of 8.6%.

Key Points: 
  • The cosmetovigilance market has seen a robust expansion, growing from $3.22 billion in 2023 to an expected $3.49 billion in 2024, with a compound annual growth rate (CAGR) of 8.6%.
  • The market is driven by factors such as stringent regulatory compliance, increased consumer awareness, global market expansion, emphasis on brand protection, and the necessity of reporting adverse events.
  • The market is projected to continue its strong growth trajectory, reaching $4.66 billion by 2028, with a CAGR of 7.5%.
  • Moreover, heightened public consciousness regarding personal care products urges consumers to seek high-quality and safe items, adding to the growth of the cosmetovigilance market.

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Retrieved on: 
Lunedì, Marzo 25, 2024
Common stock, Therapy, BID, Interim, Management

The granting of the extension follows a proactive effort by the Company to address compliance deficiencies and the presentation of a strategic plan to the Nasdaq Hearings Panel on February 1, 2024.

Key Points: 
  • The granting of the extension follows a proactive effort by the Company to address compliance deficiencies and the presentation of a strategic plan to the Nasdaq Hearings Panel on February 1, 2024.
  • The plan contained both immediate and sustained measures aimed at ensuring compliance with both the Bid Price Rule and the Equity Rule.
  • This multifaceted plan is currently being implemented and not only aims to meet Nasdaq’s immediate compliance requirements but also to strengthen the Company’s general financial position and operational efficiency.
  • Interim CEO Thomas Jensen stated, “We interpret this as Nasdaq's recognition of our efforts and confidence in our ability to execute this plan effectively.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
Venerdì, Marzo 22, 2024
Day, Ora, Dry, NCP, Conjunctiva, BID, Physiology, Patient, Pain, Ophthalmology, Observation, Blurred Vision, Doctor of Philosophy, Itch, DED, MOA, Safety, Screen time, Telecanthus, Medical director, FDA, Pharmaceutical industry

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
Giovedì, Marzo 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Retrieved on: 
Mercoledì, Marzo 20, 2024
NCP, BID, Patient, KOL, IND, DED, Safety, Pain, Telecanthus, FDA, Health, Pharmaceutical industry

The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.

Key Points: 
  • The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The KOL call will feature prominent experts in the field of dry eye disease.
  • “The upcoming data release follows the successful completion of OKYO Pharma's Phase 2 trial, which focused on assessing the efficacy and safety of OK-101, our novel topical therapeutic candidate for dry eye disease,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.